One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B Study

Ophthalmol Retina. 2019 Dec;3(12):1107-1109. doi: 10.1016/j.oret.2019.07.006. Epub 2019 Jul 26.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / pharmacokinetics
  • Bevacizumab / administration & dosage*
  • Bevacizumab / pharmacokinetics
  • Diabetic Retinopathy / complications
  • Diabetic Retinopathy / drug therapy*
  • Diabetic Retinopathy / metabolism
  • Female
  • Humans
  • Macula Lutea / pathology*
  • Macular Edema / drug therapy*
  • Macular Edema / etiology
  • Macular Edema / metabolism
  • Male
  • Plasma Kallikrein / antagonists & inhibitors
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • Tomography, Optical Coherence / methods
  • Treatment Outcome
  • Visual Acuity*

Substances

  • Angiogenesis Inhibitors
  • Bevacizumab
  • Receptors, Vascular Endothelial Growth Factor
  • Plasma Kallikrein